Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Interventional × Chalazion × Clear all

Phase

Phase NA 7 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 229 Neoplasms 171 Prostatic Neoplasms 102 Polycystic Ovary Syndrome 97 Colorectal Neoplasms 96 Carcinoma, Hepatocellular 88 Carcinoma, Non-Small-Cell Lung 74 Lung Neoplasms 59 Precursor Cell Lymphoblastic Leukemia-Lymphoma 54 Stomach Neoplasms 53 Pain 53 Neoplasm Metastasis 47 Multiple Myeloma 44 Pancreatic Neoplasms 43 Keratosis, Actinic 39 Pain, Postoperative 37 Head and Neck Neoplasms 36 Leukemia, Myeloid, Acute 35 Liver Neoplasms 34 Leiomyoma 34 Lymphoma 32 Colonic Neoplasms 32 Uterine Cervical Neoplasms 31 Recurrence 31 Brain Neoplasms 30 Papillomavirus Infections 29 Lymphoma, Follicular 28 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28 Infertility 28 Anemia 28

Interventions

Loteprednol Etabonate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00420628 2011-10-07

Pediatric Zylet Safety and Efficacy Study

Bausch & Lomb Incorporated

Phase 4 Completed

108 enrolled 11 charts

Hordeolum, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡